Setup a robust and scalable supply chain for Cell & Gene Therapies

Cell and gene therapies are delivering new treatment options for unmet needs. Often these therapies are personalized, which means that the patient is the source of the material. But their impact will be severely limited if the supporting supply chain infrastructure cannot robustly and cost-effectively connect patient to product.

Our aim is to create awareness about these complex challenges the industry currently isn’t aware it has. Our brand new whitepaper, which has been co-produced by Arvato and WorldCourier, outlines the importance of building a robust cryogenic logistics platform for allogeneic therapies that can scale up and out to support global commercialization goals.